<DOC>
	<DOCNO>NCT00115206</DOCNO>
	<brief_summary>The purpose study estimate relationship patient report outcomes ( PROs ) neutropenia ( complication ) NSCLC subject receive chemotherapy without Neulasta® ( pegfilgrastim ) .</brief_summary>
	<brief_title>Neulasta® Subjects With Advanced Non-Small-Cell Lung Cancer ( NSCLC ) During Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Nonsmall cell lung cancer , previously treat chemotherapy radiotherapy ECOG performance status 0 1 ANC great equal 2.0 x 10^9/L Cancer NSCLC within 5 year enrollment , exception surgically cure basal cell carcinoma situ carcinoma cervix Treatment le equal 30 day prior experimental agent Subjects symptomatic brain metastasis Subject currently enrol yet complete least 30 day since end investigational device drug trial ( ) receive investigational agent ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Fever</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Neulasta®</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Amgen</keyword>
</DOC>